GlassScriptPhysician profile
Kevin T Nash
NPI 1326201856
$341,342.88
in general payments reported to CMS, 2019-2025
34 companies · $42K in 2025
The $42K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $25K · 2021: $50K · 2022: $29K · 2023: $67K · 2024: $37K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Travel and Lodging: $24K · Food and Beverage: $9,045 · Consulting Fee: $4,658 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,889.00 |
| Travel and Lodging | $24,039.29 |
| Food and Beverage | $9,045.30 |
| Consulting Fee | $4,657.50 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $134,638.17 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Janssen Scientific Affairs, LLC | $119,800.63 | 2019-2023 | Tremfya |
| Abbvie INC. | $66,370.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $5,667.50 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $3,183.64 | 2023-2024 | Vtama |
| Amgen INC. | $2,390.59 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $2,280.47 | 2019-2025 | |
| Ucb, INC. | $1,927.28 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $778.35 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $646.87 | 2019-2024 | Olumiant, Taltz |
| Epi Health, LLC | $524.67 | 2019-2022 | |
| Genzyme Corporation | $481.50 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $346.98 | 2019-2021 | |
| Galderma Laboratories, L.P. | $296.02 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $272.95 | 2019-2025 | Odomzo, Blu-U, Winlevi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $241.25 | 2019-2025 | |
| Leo Pharma INC. | $220.92 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $214.47 | 2023-2025 | Zoryve |
| Allergan, INC. | $212.12 | 2019-2022 | |
| Organon LLC | $176.11 | 2025 | Vtama |
| Pfizer INC. | $139.66 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $135.59 | 2019-2021 | |
| Journey Medical Corporation | $105.56 | 2021 | |
| Incyte Corporation | $92.75 | 2021-2024 | Opzelura |
| Alexion Pharmaceuticals, INC. | $34.52 | 2025 | Strensiq |
| Merz North America, INC. | $27.96 | 2019 | |
| Haemonetics Corporation | $20.92 | 2023 | Teg Manager |
| Vyne Pharmaceuticals INC. | $20.89 | 2021 | |
| Dusa Pharmaceuticals, INC. | $17.45 | 2019 | |
| Aclaris Therapeutics, INC. | $17.15 | 2019 | |
| Celgene Corporation | $16.74 | 2019 | |
| Botanix Sb INC | $15.55 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.65 | 2022 | |
| Prugen, INC. Pharmaceuticals | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.